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Rationale, aims and objectives Lung cancer is a disease with high consumption of health care resources. The aim of this study was to describe hospital costs due to lung cancer care from diagnosis until death or end of the study follow-up, in a cohort of incident cases, by using administrative data.

Methods Particular attention was given to the determinants of total costs and the impact of the initial treatment approach on the process of costs accumulation. Incident cases were identified by the local Cancer Registry (January 2000–December 2003) among the resi-dents of Turin (Italy). Per patient hospital care has been determined from administrative databases (outpatient radiotherapy records and hospital discharge records). Costs determi-nants were identified via a multivariable generalized linear model (GLM), with a Gamma cost distribution and a logarithmic link function. To assess the time effect over the cost accumulation process for non-small-cell lung cancer cases, the same GLM Gamma model was repeated at different follow-up periods. Analyses were stratified by cancer histotype. Results Results evidenced the relevant role of initial patterns of care on the cost accumu-lation process, with increased midterm costs associated with curative patterns of care.









Lung cancer is a disease with high consumption of health care resources because of its high incidence [1]. A study by Yabroff et al. identified lung and colorectal cancers as the most costly cancers in the USA for the elderly [2]. Previous cost estimates from SEER-Medicare database showed lung cancer as the most expensive single cancer for both genders, after colorectal cancer and prostate in men and breast in women [3]. From 1991 to 2002, there was a statistically significant increase in the initial care cost for lung cancer among Medicare beneficiaries [4].

Many studies have estimated lifetime per patient lung cancer health care costs. The main cost driver was hospitalization, accounting for a percentage ranging from 50% to 70% of total direct costs [5–10]. The majority of costs are incurred around the date of diagnosis [9], for the initial staging and treatment [6,11].

Access to appropriate care is considered an important predictor of lung cancer patients’ prognosis. A previous study in our city (Turin, Italy) [12] analysed factors associated with the probability of accessing a curative pattern of care in a cohort of non-small-cell lung cancer (NSCLC) incident cases and their subsequent prog-nosis. Initial patterns of care are also expected to have an impact on the subsequent lifetime cost of care. In particular, the descrip-tion of the association among the initial patterns of care and the costs accumulation process allow the prediction of the economic burden over the lifetime of the patients.

The utilization of administrative data for monitoring health care delivered to patients has been widely described [13]. The linkage between different databases may lead to an efficient way of gathering data on individual patterns of care [14] and their related costs. Still, linkage among cancer registries and administrative data provides a population-based overview.








A cohort of lung cancer incident cases (IDC9 162.0–162.9) was selected from the Piedmont Cancer Registry of Turin (PCRT) during the period January 2000–December 2003, among the resi-dents of Turin (Italy). The PCRT provides data on the following patient characteristics: gender, age at diagnosis, cancer histotype, and vital status at the date of periodical follow-up verification. Patient survival was updated at January 2006 (from 3 to 6 years of follow-up).

Per patient hospital care has been determined from administra-tive databases (outpatient radiotherapy records and Hospital Dis-charge Records – HDRs) during the period 2000–2006, using a record linkage procedure based on the tax identification number. Hospital treatment costs were analysed as per patient lifetime costs. To determine the care associated with the treatment of lung cancer, the complete pattern of care was defined as the care pro-vided from 6 months before diagnosis up to death, or a maximum of 4 years after diagnosis. For a few long-term survivors, the end of follow-up was limited to 4 years in order to have a homoge-neous time horizon for all the cases.

Episodes of care not specifically related to lung cancer were ignored. Selection criteria for identifying episodes of care related to lung cancer were described in depth in a previous publication [12].

Episodes of care costs were estimated by using regional tariffs (euros), as rewarded to hospitals by the Regional National Health Service (NHS). Costs were updated to year 2007 using the con-sumer price index [15].

Subjects were classified into three hierarchical groups in rela-tion to the initial patterns of care (180 days before and after the incidence date): (1) curative surgical care (ICD9-CM: 3229– 3290); (2) radiotherapy and/or chemotherapy; and (3) other non-curative or no care. The third group included also patients receiving hospital care after the first 6 months from diagnosis.

Educational level was classified into four levels: high (univer-sity degree), intermediate (high school or some secondary educa-tion), low (elementary school), missing (not declared). Marital status was defined as married, unmarried (single, separated, divorced, or widowed), or unknown, where information was not declared.

The Charlson co-morbidity index, as adapted by Romano et al. [16] for use with ICD9-CM diagnoses from claims data, was used to determine the extent of chronic illness with prognostic rel-evance. The index was calculated by weighing 19 medical condi-tions recorded in the HDRs occurring during the year before the diagnosis date, and the 6 months after. This time window enabled proper management of all the available information around the date of diagnosis.

The lung cancer stage was not directly available in the HDRs. It was derived from the coded diagnoses of the HDR selected to define the initial pattern of care. All ICD9-CM codes of distant metastasis, lymph node involvement or local invasion were selected and combined according to the Disease Staging coded criteria [17,18]. Patients were classified as: early stage (stage

#2.1, corresponding to stages IA-IIB of the TNM classification) or advanced stage (stage 3.1 or greater).







Table 1 Characteristics of a cohort of incident lung cancer patients (zero-costs excluded), by histotype. Years 2000–2003, Piedmont, Italy












































NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer

Table 2 Per patient cumulative hospitalization costs (€) at the end of the follow-up by characteristics (zero-costs excluded) and histotype. Years 2000–2003, Piedmont, Italy

	NSCLC (n = 2323)				SCLC (n = 250)		
					
Variable	Mean (SD)	Median (IQ–IIIQ)	Mean (SD)	Median (IQ–IIIQ)
								
Total	15 143	(12 414)	11 830	(6 520–20 304)	19 123	(13 936)	16 762	(7 648–26 712)
Age									
65	19 867	(14 462)	16 292	(9 691–25 770)	22 227	(13 802)	19 793	(14 476–28 961)
65–69	17 368	(12 815)	14 297	(8 192–23 618)	23 430	(15 885)	20 438	(11 045–30 841)
70–74	14 588	(10 681)	11 907	(7 044–19 739)	17 750	(13 533)	13 986	(6 855–26 413)
74	10 733	(9 626)	7 551	(4 136–13 741)	12 032	(9 388)	8 680	(5 052–15 794)
Gender									
Male	15 131	(12 463)	11 784	(6 573–20 320)	18 404	(12 884)	16 734	(7 303–25 522)
Female	15 185	(12 257)	12 043	(6 448–20 182)	21 169	(16 512)	17 011	(8 967–29 520)
Education									
High	16 336	(12 594)	13 325	(6 921–22 004)	20 540	(12 245)	19 489	(13 520–26 744)
Intermediate	17 907	(13 985)	14 343	(7 856–24 165)	19 393	(17 365)	14 880	(7 213–26 712)
Low	15 015	(12 153)	11 985	(6 770–19 739)	19 816	(13 405)	17 553	(8 595–28 418)
Not available	10 302	(8 385)	8 192	(4 218–13 717)	15 956	(10 438)	17 192	(6 684–22 174)
Marital status									
Married	15 746	(12 455)	12 533	(7 233–20 611)	15 746	(12 455)	12 533	(7 233–20 611)
Other	14 816	(12 650)	10 868	(5 463–20 749)	14 816	(12 650)	10 868	(5 463–20 749)
Not available	7 698	(7 033)	5 233	(3 684–8 682)	7 698	(7 033)	5 233	(3 684–8 682)
Co-morbidity									
No co-morbidity	15 067	(12 122)	11 718	(6 294–20 472)	18 256	(12 354)	16 734	(7 401–24 825)
One or more	15 780	(12 867)	12 376	(7 192–20 558)	20 896	(15 762)	17 890	(8 221–30 102)
co-morbidities									
Disease staging									
Early stage	16 588	(13 222)	13 285	(7 349–22 247)	21 534	(15 213)	18 610	(10 010–29 345)
Advanced stage	13 941	(11 283)	10 588	(5 850–18 368)	17 404	(12 099)	15 034	(7 394–23 590)
Initial patterns of care									
Surgery	23 662	(14 222)	20 285	(13 696–28 680)	24 660	(8 737)	26 712	(14 522–28 249)
Radiation/chemotherapy	17 319	(12 240)	14 636	(8 666–23 267)	22 448	(13 414)	19 828	(13 514–30 036)
Non-curative care	9 147	(8 415)	6 913	(3 789–11 369)	7 849	(9 519)	5 045	(3 749–8 007)
Follow-up duration (months)									
#3	6 689	(5 944)	4 986	(3 720–8 198)	6 446	(3 776)	5 038	(3 749–7 939)
3–6	11 727	(8 208)	10 783	(6 456–14 981)	16 806	(11 970)	14 522	(8 280–20 069)
6–18	17 289	(10 731)	15 435	(9 724–22 685)	21 794	(11 458)	20 001	(14 476–28 704)
18	23 318	(15 078)	20 384	(12 277–31 142)	30 720	(15 756)	27 534	(19 489–44 389)
Survival at 4 years									
No	18 102	(12 537)	15 037	(9 655–23 618)	29 252	(16 498)	25 369	(16 318–46 556)
Yes	14 812	(12 359)	11 433	(6 090–19 805)	18 612	(13 637)	16 640	(7 401–25 522)








Hospital care supplied to lung cancer patients, by histotype [small-cell lung cancer (SCLC) and NSCLC], was described by identify-ing clinical patterns through administrative sources. Total costs at the end of the follow-up period were analysed in relation to the following covariates: age, gender, Charlson co-morbidity index, educational level, marital status, initial patterns of care, follow-up duration and death. Differences among groups were tested by using the nonparametric Kruskal–Wallis test because of the skewness in costs.

Zero-cost observations were excluded from the analysis because of the lack of information on any relevant covariate besides age and gender. To assess the possibility of a selection bias, these excluded cases were compared to those included on the basis of the available characteristics.
The impact of the available covariates on total costs, stratified by histotype, was modelled via a multivariable generalized linear model (GLM), with a Gamma cost distri-bution and a logarithmic link function. Covariates have been selected in a backward fashion using the Akaike

Information	Criterion	with   a	significance	threshold   of





























One or more co-morbidities	19.18	(12.51; 26.24)	0.175	0.029	0.001
Intermediate education	7.03	(-1.83; 16.7)	0.068	0.044	0.1236
Low education	3.02	(-4.91; 11.62)	0.030	0.041	0.4662
Education not available	-18.68	(-26.09; -10.52)	-0.207	0.049	0.001
Female gender	4.99	(-1.73; 12.17)	0.049	0.034	0.149
Death	133.36	(103.99; 166.96)	0.847	0.069	0.001














NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer.































Note: Estimates are adjusted by age, gender, and educational level.
Table 4 Effect of the initial patterns of care on total costs at different follow-up times for non-small-cell lung cancer cases

Among the 2573 analysed subjects, 2323 (90.3%) were NSCLC cases and 250 (9.7%) were SCLC. Table 1 describes the patients’ characteristics by histotype.

Total hospitalization costs until the end of the follow-up period, by several patients’ characteristics, are described in Table 2, stratified by histotype. Cumulative costs differed across histotypes and were statistically significant (P  0.0001): SCLC cases showed higher costs (mean cost: €19 123; median cost: €16 762) compared with NSCLC (mean cost: €15 143; median cost: €11 830).
The multivariable regression model enabled to describe the mul-tiplicative effect of several characteristics on the total costs (Table 3).

Among NSCLC cases, patients that were surgically treated had significantly higher long-term costs. Radiotherapy and/or chemo-therapy as initial care determined a decrease in costs of around 11% (95% CI: -18.92; -1.32) Accessing only other non-curative care determined a further decrease in costs of around 40% (95% CI: -45.75; -32.67). The other relevant factor in decreasing costs was the patient’s age in years (-1.41; 95% CI: -1.71; -1.11).
Factors increasing the costs were: the presence of one or more co-morbidities (+19.18%; 95% CI: +12.51; +26.24), the duration of follow-up, measured in years (+2.57%; 95% CI: +2.3; +2.85) and the patient’s death (+133.36%; 95% CI: +103.99; +166.96).

For the SCLC cases, costs were increased by the presence of co-morbidities (+26.65%; 95% CI: +7.79; +48.81), by the patient’s death (+275.93%; 95% CI: +122.38; +535.52) and by the monthly follow-up duration (+4.51%; 95% CI: +3.43; +5.61). Non-curative patterns of care demonstrated a significantly decrease in costs (-45.66%; 95% CI: -56.44; -32.21).

The impact on costs due to the initial patterns of care over time is described in Table 4. The overall increase in costs due to surgical pattern of care compared with a chemo/radiotherapy and non-curative care is not evident in the short run (3–6 months). On the contrary, the non-curative pattern of care showed higher costs in the first 3 months (+28.41%; 95% CI: +13.83; +44.87). After 12 months, costs accumulated in the surgically treated group are steadily higher than in the other two groups.





This study analysed the hospitalization costs incurred by the NHS for caring lung cancer patients from diagnosis to death or a maximum of 4 years of follow-up. The relevant role of the initial patterns of care on the cost accumulation process has been evi-denced, with increased mid-term costs associated with curative patterns of care.

For NSCLC patients the higher costs estimated for surgically treated subjects were due to treatments supplied in the mid-term (12, 24, 36 months), but not to a more expensive initial treatment. A longer duration of the follow-up was associated with higher hospital costs even if the analysis was only run by including episodes of care related to lung cancer and not including care provided for other causes. Together with the non-linear cost accu-mulation process during follow-up, this fact is likely to be due to the presence of recurrences and is in line with the results of Park et al. [22] evidencing a U-shape annual cost curve in the recur-rence group.

An older age was associated with lower hospitalization costs, mainly due to a lower number of admissions. This result confirms earlier findings by Shugarman et al. [23] referring to the last year of life.

As expected, presence of co-morbidities and death were strong predictors of higher costs.

This study was intended to analyse the impact of the initial treatment approach on the subsequent hospital costs accumulation process during a reasonable follow-up. Since hospital costs have been evidenced by several studies as the main cost driver in treat-ing lung cancer, accounting from 50% [6,8,24] to 70% [7]–80% [25] of total direct costs, we believe that an in-depth analysis of their determinants is of extreme interest. In addition, the analysis of total health care costs would allow for a better understanding of the NHS resources consumption due to lung cancer.
Our study has some limitations. Because the study was per-formed in relation to the incident cases during the period 2000– 2003, at present the observed patterns of care are likely to have changed in our region. The routine introduction of FDG-PET (positron emission tomography with fluoro-deoxy-glucose) scan-ning in particular should allow for a better staging of cancer, reducing the probability of recurrences after surgery. As a conse-quence, costs incurred during the follow-up after surgery could be reduced on average. Another study weakness is the lack of data on chemotherapy: the cost of some newer, highly expensive drugs may be largely underestimated using the tariffs for outpa-tients visits.

The major advantage of the current study is to provide an esti-mate of the lung cancer costs of hospital care at population level, by using administrative data, readily available at low costs. In the USA, administrative data have been recognized as an essential source of information for studying the financial burden of disease [26]. This study provides an application of such tools to a health care problem with high social and economic burden at the Euro-pean level.
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